Difference between revisions of "Part:BBa J58100"
(One intermediate revision by the same user not shown) | |||
Line 2: | Line 2: | ||
<partinfo>BBa_J58100 short</partinfo> | <partinfo>BBa_J58100 short</partinfo> | ||
− | Two heterologous prokariotic activators, the bacteriophage lambda cI protein, and the E. coli cyclic AMP receptor protein (CRP), activate transcription synergistically from an artificial promoter bearing binding site for both proteins. Both proteins interact directly with RNA polymerase and bind DNA at two operator sites. | + | We have designed a promoter synergistically activated by two transcription factors. We have used the part <partinfo>I12007</partinfo> as starting point, together with the ideas of the paper by Joung et al. Two heterologous prokariotic activators, the bacteriophage lambda cI protein, and the E. coli cyclic AMP receptor protein (CRP), activate transcription synergistically from an artificial promoter bearing binding site for both proteins. Both proteins interact directly with RNA polymerase and bind DNA at two operator sites. |
'''By Valencia iGEM 2006''' | '''By Valencia iGEM 2006''' | ||
− | A. Aparici (2), MC. Aroca (2), J. Carrera (1), C. Edo (1,2), G. Fuertes (2), D. Jimenez (2), C. Mata (2), JV. Medrano (2), A. Montagud (2), C. Navarrete (2), E. Navarro (1), G. Rodrigo (1), M. Baguena (1), P. Tortosa (3), P. Fernandez-de-Cordoba (1), A. Ferrando (2), J. Salgado (2), J. Urchueguia (1), A. Jaramillo (3). | + | ''A. Aparici (2), MC. Aroca (2), J. Carrera (1), C. Edo (1,2), G. Fuertes (2), D. Jimenez (2), C. Mata (2), JV. Medrano (2), A. Montagud (2), C. Navarrete (2), E. Navarro (1), G. Rodrigo (1), M. Baguena (1), P. Tortosa (3), P. Fernandez-de-Cordoba (1), A. Ferrando (2), J. Salgado (2), J. Urchueguia (1), A. Jaramillo (3).'' |
− | 1 Universidad Politecnica de Valencia, Spain | + | ''1 Universidad Politecnica de Valencia, Spain'' |
− | 2 Universitat de Valencia, Spain | + | ''2 Universitat de Valencia, Spain'' |
− | 3 Ecole Polytechnique, France | + | ''3 Ecole Polytechnique, France'' |
Line 21: | Line 21: | ||
<span class='h3bb'>Sequence and Features</span> | <span class='h3bb'>Sequence and Features</span> | ||
<partinfo>BBa_J58100 SequenceAndFeatures</partinfo> | <partinfo>BBa_J58100 SequenceAndFeatures</partinfo> | ||
− | + | The CRP binding site contains an XbaI site that could not be removed without compromising the promoter's activity. Avoid using XbaI when using this part. A new part is under development that will have a mutated but functional CRP binding site. | |
<!-- Uncomment this to enable Functional Parameter display | <!-- Uncomment this to enable Functional Parameter display |
Latest revision as of 21:17, 29 October 2006
AND-type promoter synergistically activated by cI and CRP
We have designed a promoter synergistically activated by two transcription factors. We have used the part BBa_I12007 as starting point, together with the ideas of the paper by Joung et al. Two heterologous prokariotic activators, the bacteriophage lambda cI protein, and the E. coli cyclic AMP receptor protein (CRP), activate transcription synergistically from an artificial promoter bearing binding site for both proteins. Both proteins interact directly with RNA polymerase and bind DNA at two operator sites.
By Valencia iGEM 2006
A. Aparici (2), MC. Aroca (2), J. Carrera (1), C. Edo (1,2), G. Fuertes (2), D. Jimenez (2), C. Mata (2), JV. Medrano (2), A. Montagud (2), C. Navarrete (2), E. Navarro (1), G. Rodrigo (1), M. Baguena (1), P. Tortosa (3), P. Fernandez-de-Cordoba (1), A. Ferrando (2), J. Salgado (2), J. Urchueguia (1), A. Jaramillo (3).
1 Universidad Politecnica de Valencia, Spain
2 Universitat de Valencia, Spain
3 Ecole Polytechnique, France
Sequence and Features
- 10INCOMPATIBLE WITH RFC[10]Illegal XbaI site found at 11
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23INCOMPATIBLE WITH RFC[23]Illegal XbaI site found at 11
- 25INCOMPATIBLE WITH RFC[25]Illegal XbaI site found at 11
- 1000COMPATIBLE WITH RFC[1000]
The CRP binding site contains an XbaI site that could not be removed without compromising the promoter's activity. Avoid using XbaI when using this part. A new part is under development that will have a mutated but functional CRP binding site.